BRNS

Barinthus Biotherapeutics Plc. - 10-Q Summary (Q3 2025)

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Barinthus Biotherapeutics Plc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for autoimmune and inflammatory diseases (I&I) using its SNAP-TI platform. The company's lead candidate, VTP-1000 for celiac disease, is in Phase 1 trials. On September 29, 2025, the company entered into a definitive merger agreement to combine with Clywedog Therapeutics, Inc., a transaction expected to close in the first half of 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to zero from $14.97 million in the prior year quarter due to the cessation of license payments from Oxford University Innovation related to Vaxzevria commercial sales, following AstraZeneca's withdrawal of marketing authorization in Europe.
• Impairment Charge: The company recorded a non-cash impairment charge of $4.67 million on intangible assets (acquired development technology) in Q3 2025. This was triggered by the merger agreement with Clywedog, where the indicative offer price was below the fair value of net assets.
• Expense Reduction: Research and Development (R&D) expenses decreased by 52% ($5.75 million) and General and Administrative (G&A) expenses decreased by 61% ($8.26 million) compared to Q3 2024. This reflects a strategic pivot to focus solely on I&I programs, workforce reductions, and the closure of the U.K. laboratory.
• Foreign Exchange Impact: G&A expenses included a $3.0 million foreign exchange gain in Q3 2025, contrasting with a $7.7 million loss in the same period in 2024.

Guidance, Outlook, and Risks

• Merger Transaction: The company is combining with Clywedog Therapeutics. Upon closing, Barinthus will become a wholly-owned subsidiary of Topco, and the combined entity will trade under the ticker "CLYD." The transaction is subject to shareholder approval and regulatory conditions.
• Liquidity: Management expects current cash resources ($75.7 million) to fund operations into the start of 2027, assuming the merger does not close or additional funding is not required sooner. The company does not expect positive cash flows from operations in the foreseeable future.
• Strategic Pivot: The company has deprioritized infectious disease and oncology programs (e.g., VTP-500 MERS, VTP-850) to focus resources on the SNAP-TI platform and VTP-1000.
• Risks: Key risks include the failure to consummate the merger, potential dilution of shareholders, inability to secure additional funding if the merger fails, and the inherent uncertainties of clinical development. The filing also notes risks related to U.S. government shutdowns impacting FDA/SEC review timelines.

Investor Verification Checklist

• Merger Terms: Verify the final exchange ratio (1 Barinthus share for 1 Topco share; 1 Clywedog share for ~4.36 Topco shares) and the expected closing timeline (H1 2026).
• Cash Runway: Confirm the $75.7 million cash balance and the validity of the "into start of 2027" burn rate projection given the ongoing merger costs.
• Impairment Details: Review Note 7 for the specific fair value methodology used to determine the $4.67 million impairment charge on intangible assets.
• CEPI Grant Status: Verify the status of the Coalition for Epidemic Preparedness Innovations (CEPI) funding agreement for VTP-500, as the company intends to exit this agreement.
• Share Count: Note the outstanding share count of approximately 40.8 million ordinary shares as of October 30, 2025.